Ixazomib (Ninlaro) combination rejected for multiple myeloma in second draft guidance
The National Institute for Health and Care Excellence (NICE) has again rejected ixazomib (Ninlaro) in combination with lenalidomide and dexamethasone (IRd) for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more previous therapies.
(Reuters) - Johnson&Johnson's blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with standard therapy alone in patients not previously treated for the blood cancer, according to data released on Tuesday.
Patient advocate, Jeff Folloder, and Dr. Gareth Morgan from The UAMS Myeloma Institute discuss what monoclonal antibodies can do for myeloma patients and what the next step is for effective treatment.... Author: patientpower Added: 11/21/2017
Melanie House, a physical therapist from the University of Iowa Hospitals and Clinics, shares simple steps and at-home strategies for myeloma patients experiencing neuropathy to achieve better balance... Author: patientpower Added: 11/21/2017
Can being physically fit sway a healthcare committee to change their vote for a transplant? Find out from Jim Bonds story of survival how exercise can influence transplant candidacy. He also shares h... Author: patientpower Added: 11/21/2017
There is some agreement within the multiple myeloma (MM) community regarding the importance of combination chemotherapy, transplant, personalized therapy and minimal residual disease. These hot topics... Author: VJHemOnc Added: 11/21/2017
We report a case of CD138-low MSP with 17p deletion in a patient with relapsed SBP. 17p deletion is associated with a poor outcome in patients with MM, and the low expression of CD138 in myeloma cells is associated with drug resistance and a poor prognosis. The patient was successfully treated with bortezomib plus dexamethasone induction therapy and autologous hematopoietic stem cell transplantation followed by bortezomib maintenance therapy. Consequently, bortezomib treatment was stopped and a stringent complete response has been maintained. PMID: 29151530 [PubMed - as supplied by publisher]
Authors: Maki H, Nannya Y, Imai Y, Yamaguchi S, Kamikubo Y, Ichikawa M, Nakamura F, Kurokawa M Abstract Ascites is a rare complication of multiple myeloma (MM); in most cases, the direct invasion of myeloma cells to the peritoneal cavity has been assumed to be the etiology because the effusion is usually exudative and contains a high proportion of myeloma cells. We herein report a case of MM with massive ascites containing only a small amount of myeloma cells. Instead, high levels of serum and ascitic VEGF were detected. This was suggested to be a potential mechanism underlying the development of ascites. PMID:...
(Reuters) - Johnson&Johnson's blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with the standard therapy alone in patients not previously treated for the blood cancer, according to data released on Tuesday.
Treatment of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome should be directed at the underlying plasma cell clone with risk-adapted therapy based on the extent of the plasma cell disorder. Radiation therapy is effective for patients with a localized presentation, without bone marrow involvement, and 1 to 3 bone lesions. Patients with disseminated disease should receive, preferably, high-dose chemotherapy with peripheral blood transplantation. Low-dose melphalan and dexamethasone or new agents used in myeloma are also effective. The most promising agent is lenalidomid...